Welcome to our dedicated page for Utah Med Prods SEC filings (Ticker: UTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page presents Utah Medical Products, Inc. (UTMD) filings with the U.S. Securities and Exchange Commission, along with AI-generated highlights to help interpret the disclosures. As a Nasdaq-listed medical device manufacturer, Utah Medical Products files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, among other documents.
In its periodic reports, the company provides detailed discussions of revenues, gross profit, operating income, income before tax and net income, broken out by domestic and outside-the-U.S. sales, direct versus OEM channels, and key product categories such as biopharma pressure monitoring devices, Filshie Clip System devices and blood pressure monitoring kits. Management also describes the impact of foreign currency exchange rates, tariffs, litigation expenses and amortization of identifiable intangible assets on its results.
Current reports on Form 8-K capture specific material events. Recent 8-K filings have included the release of quarterly financial information under Item 2.02 and the appointment of a new director, Kevin Timken, under Item 5.02, along with details of his committee roles, stock option grant and cash board fees. Another 8-K disclosed an increase in the company’s regular quarterly cash dividend under Item 8.01.
Stock Titan’s tools surface these filings as they appear on EDGAR and provide AI-powered summaries that explain the key points in plain language. Users can quickly scan 10-K and 10-Q discussions of segment performance, margins and risk factors, review 8-K announcements about dividends or board changes, and examine exhibits attached to the filings. Form 4 insider transaction reports, proxy statements and other documents, when available, can also be reviewed here to build a fuller picture of Utah Medical Products’ governance, compensation and insider activity.
Utah Medical Products (UTMD) reported Q2 2025 net sales of $9,953 thousand, down 4.3% from $10,400 in Q2 2024, and first-half sales of $19,663 thousand, down 9.6% year-over-year. Gross profit fell to $5,595 thousand (56.2% margin) from $6,253 thousand (60.1%), driven by lower volumes, an unfavorable product mix in Ireland and reduced orders from former large OEM customer PendoTECH. Net income was $3,048 thousand in Q2 and $6,089 thousand for 1H 2025; diluted EPS were $0.94 and $1.86, respectively.
The company remains well capitalized with $82.2 million in cash and investments, no debt, ongoing dividends and opportunistic share repurchases (119,255 shares repurchased in 1H 2025 for $6.7 million). Management expects full-year PendoTECH sales to be about $2.0 million lower than 2024, is tracking adjusted EBITDA near targets, and highlights potential OUS tariff and distributor-timing risks that could affect 2H results.